Taken together, our findings demonstrate that NPY (6–20) plays a bimodal role on the regulation of HSC function in BM and could be used for the treatment of both osteoporosis and chemotherapy-related bone marrow failure. Here, NPY is linked to Bone marrow hypocellularity.